Table 1.
Tumor and patient characteristics in IDH-mut dLGG by WHO grade.
| All dLGG IDH-mut | WHO grade 2 dLGG IDH-mut | WHO grade 3 dLGG IDH-mut | p-value* | |
|---|---|---|---|---|
| (n = 168) | (n = 85) | (n = 83) | ||
| Age, median (Q1-Q3) | 41 (33.0–52.8) | 42 (33.5–52.5) | 40 (32.0–53.0) | 0.26 |
| Female, n (%) | 69 (41.1) | 35 (41.2) | 34 (41.0) | 0.98 |
| KPS ≤ 80 | 66 (39.3) | 29 (34.1) | 37 (44.6) | 0.21 |
| Focal deficit, n (%) | 28 (16.7) | 14(16.5) | 14 (16.9) | 1.00 |
| Asymptomatic/incidental finding, n (%) | 13 (7.7) | 12 (14.1) | 1 (1.2) | 0.002 |
| Max tumor diameter in mm, mean (SD) | 56.3 (19.4) | 55.2 (19.6) | 57.3 (19.3) | 0.48 |
| Eloquence, n (%) | 111 (66.1) | 59 (69.4) | 52 (62.7) | 0.43 |
| Any CE, n (%) | 81 (48.8) | 28 (33.3) | 53 (64.6) | <0.001 |
| missing | n=2 | n=1 | n=1 | |
| Bilateral growth, n (%) | 19 (11.3) | 8 (9.4) | 11 (13.3) | 0.43 |
| Tumor border, n (%) | 1.0 | |||
| absent | 20 (12.0) | 10 (11.8) | 10 (12.3) | |
| conspicuous or mild | 146 (88.0) | 75 (88.2) | 71 (87.7) | |
| missing | n=2 | n=2 | ||
| Mainly frontal location, n (%) | 104 (61.9) | 51 (60.0) | 53 (63.9) | 0.64 |
| 1p19q-codeletion, n (%) | 79 (46.4) | 41 (48.2) | 38 (44.6) | 0.76 |
| Ki-67%, mean (SD) | 2.5 (3.6) | 1.7 (2.2) | 3.3 (4.3) | 0.007 |
| missing | n=45 | n=29 | n=16 | |
| Homozygous loss of CDKN2A/B, n (%) | 11 (9.3) | 1 (1.9) | 10 (15.2) | 0.022 |
| missing | n=50 | n=33 | n=17 | |
| Biopsy only, n (%) | 9 (5.4) | 4 (4.8) | 5 (6.1) | 0.74 |
| Residual volume ml, median (Q1-Q3) | 8.9 (1.4–25.4) | 9.1 (1.3–22.3) | 8.9 (1.6–31.8) | 0.51 |
| Early postoperative chemotherapy** | 89 (53.9) | 29 (34.1) | 60 (75.0) | <0.0001 |
| missing | n=3 | n=3 | ||
| Any postoperative chemotherapy | 135 (82.3) | 62 (73.8) | 73 (91.3) | 0.004 |
| missing | n=4 | n=1 | n=3 | |
| Early postoperative radiotherapy** | 98 (58.7) | 32 (37.6) | 66 (80.5) | <0.0001 |
| missing | n=1 | n=1 | ||
| Any postoperative radiotherapy | 139 (84.2) | 64 (77.1) | 75 (91.5) | 0.02 |
| missing | n=3 | n=2 | n=1 | |
| Early postoperative chemo- or radiotherapy** | 119 (71.3) | 41 (48.2) | 78 (95.1) | <0.0001 |
| missing | n=1 | n=1 | ||
| Early postoperative radio-chemotherapy (both)** | 68 (41.2) | 20 (23.5) | 48 (60.0) | <0.0001 |
| missing | n=3 | n=3 | ||
| Deceased, n (%) | 57 (33.9) | 26 (30.6) | 31 (37.3) | 0.41 |
| Survival years, median (95%CI) | 10.2 (8.5–11.9) | 11.4 (8.7–14.1) | 10.0 (7.4–12.6) | 0.54 |
KPS, Karnofsky Performance Status; CE, contrast enhancement.
*Comparing WHO grade 2 and WHO grade 3.
**Early therapy was defined as treatment within 6 months after surgery.
Bold text indicates p-value <0.05.